iCAD Announces Positive Three-Year Data Using the Xoft System to Treat Skin Cancer Presented at ASTRO

  iCAD Announces Positive Three-Year Data Using the Xoft System to Treat Skin
  Cancer Presented at ASTRO

 Data Demonstrates Effective Long-term Treatment with No Recurrences and Good
                              Cosmetic Outcomes

2013 ASTRO Annual Meeting

Business Wire

NASHUA, N.H. & ATLANTA -- September 24, 2013

– Booth Number 2449 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider
of advanced image analysis, workflow solutions and radiation therapy for the
early identification and treatment of cancer, today announced that positive
data using the Company’s Xoft^® Axxent^® Electronic Brachytherapy System^® to
treat non-melanoma skin cancer (NMSC) were presented today at the American
Society of Radiation Oncology’s (ASTRO) 55^th Annual Meeting being held from
September 22-25, 2013 in Atlanta. The data show that at three years
post-treatment, patients who had high dose rate (HDR) electronic brachytherapy
with the Xoft System had good cosmesis, low toxicity levels and no
recurrences. The Xoft System is the only electronic brachytherapy system with
peer reviewed published clinical data supporting its use in skin cancer. More
than 2,000 NMSC patients have been successfully treated with the Xoft System.

Ajay Bhatnagar, MD, MBA, Cancer Treatment Services Arizona, Affiliate of 21^st
Century Oncology, Adjunct Assistant Professor of Radiation Oncology,
University of Pittsburgh School of Medicine and DermEbx, presented clinical
outcomes data on 187 patients with 275 NMSC lesions treated with HDR
electronic brachytherapy with surface applicators, using the Xoft System.
One-year data on this patient cohort was published in the journal
Brachytherapy in March/April 2013.

“At three years post-treatment, we are continuing to see highly encouraging
results with the Xoft System related to cosmesis and toxicity with no
recurrences in non-melanoma skin cancer patients treated with HDR electronic
brachytherapy,” said Dr. Bhatnagar. “We’ve found the Xoft System to be an
ideal option for many patients, including the elderly, as the treatment
schedule is convenient and it is significantly less invasive, allowing
patients to complete their treatment plan and get back to their lives.”

“We are pleased with the positive data and successful outcomes for those
patients treated with the Xoft System for non-melanoma skin cancer. Dr.
Bhatnagar’s study demonstrates the effectiveness of the technology three years
post-treatment—a significant milestone for the radiation oncology community,”
said Ken Ferry, President and CEO of iCAD. “Evidence is mounting in favor of
this convenient, non-surgical, and effective treatment option that allows more
skin cancer patients to receive radiation therapy.”

About Non-Melanoma Skin Cancer

NMSC, identified as either basal cell carcinoma or squamous cell carcinoma, is
not only the most common type of skin cancer, it is the most common type of
cancer in humans. These cancers commonly appear on sun-exposed areas of the
body such as the face, ears, neck, lips, and backs of the hands. NMSC affects
approximately 2.2 million Americans each year.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S.
Food and Drug Administration and CE marked in the EU for use anywhere in the
body, including for the treatment of early stage breast cancer, endometrial
cancer, cervical cancer and skin cancer. It utilizes a proprietary
miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. A
post-market study is underway to assess the safety and efficacy of
Intraoperative Radiation Therapy with the Xoft System. Xoft is a wholly owned
subsidiary of iCAD, Inc. For more information about Xoft visit
www.xoftinc.com.

About iCAD, Inc.

iCAD is a leading provider of advanced image analysis, workflow solutions and
radiation therapies for the early identification and treatment of common
cancers. iCAD offers a comprehensive range of high-performance, upgradeable
CAD solutions for mammography and advanced image analysis and workflow
solutions for Magnetic Resonance Imaging, for breast and prostate cancers and
Computed Tomography for colorectal cancer. iCAD’s Xoft System offers radiation
treatment for early-stage breast cancer that can be administered in the form
of intraoperative radiation therapy or accelerated partial breast irradiation.
The Xoft System is also cleared for the treatment of non-melanoma skin cancer,
cervical cancer and endometrial cancer. For more information, call
877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995:

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the Company’s
ability to identify a replacement for the Axxent FlexiShield Mini, the risks
relating to the Company’s acquisition of Xoft including, the expected benefits
of the acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”,
“likely”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under
no obligation to provide any updates to any information contained in this
release. For additional disclosure regarding these and other risks faced by
iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.

Contact:

For iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
For iCAD investor relations
Anne Marie Fields of LHA, 212-838-3777 x6604
fields@lhai.com
or
For iCAD media inquiries
Helen Shik of Schwartz MSL, 781-684-0770
iCAD@schwartzmsl.com
 
Press spacebar to pause and continue. Press esc to stop.